Alzamend Neuro (ALZN) Cash & Equivalents (2020 - 2026)

Alzamend Neuro has disclosed Cash & Equivalents across 7 years of filings, most recently posting $710689.0 for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 82.0% year-over-year to $710689.0; the TTM figure through Apr 2026 stood at $710689.0 (down 82.0% YoY), while the FY2026 annual figure was $710689.0, down 82.0% from the prior year.
• Cash & Equivalents came in at $710689.0 for Q2 2026 at Alzamend Neuro, down from $2.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $11.8 million in Q1 2022 to a low of $200079.0 in Q4 2023.
• Average Cash & Equivalents over 5 years is $4.3 million, with a median of $3.9 million recorded in 2025.
• Year-over-year, Cash & Equivalents surged 28842.46% in 2022 and tumbled 97.82% in 2023.
• Over 5 years, Cash & Equivalents stood at $9.2 million in 2022, then plunged by 97.82% to $200079.0 in 2023, then surged by 1945.73% to $4.1 million in 2024, then advanced by 8.71% to $4.4 million in 2025, then tumbled by 84.03% to $710689.0 in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $710689.0 in Q2 2026, $2.7 million in Q1 2026, and $4.4 million in Q4 2025.